Earnings summaries and quarterly performance for INSMED.
Executive leadership at INSMED.
Board of directors at INSMED.
Research analysts who have asked questions during INSMED earnings calls.
Jason Zemansky
Bank of America
8 questions for INSM
Also covers: ABOS, BBIO, CYTK +5 more
JF
Jessica Fye
JPMorgan Chase & Co.
8 questions for INSM
Also covers: ALKS, ALNY, AMRN +23 more
JS
Joseph Schwartz
Oppenheimer
8 questions for INSM
Also covers: ASND, AUPH, BMRN +14 more
RB
Ritu Baral
TD Cowen
8 questions for INSM
Also covers: ACAD, ALNY, ATAI +11 more
Vamil Divan
Guggenheim Securities
8 questions for INSM
Also covers: ABBV, ABSI, ANIP +7 more
AN
Andrea Newkirk
Goldman Sachs
6 questions for INSM
Also covers: ABCL, ALKS, ARWR +9 more
Graig Suvannavejh
Mizuho Securities
6 questions for INSM
Also covers: ADAP, ADVM, ALEC +11 more
Jennifer Kim
Cantor Fitzgerald
6 questions for INSM
Also covers: BLTE, CPRX, EYPT +1 more
Liisa Bayko
Evercore ISI
5 questions for INSM
Also covers: ALT, BCRX, IPHA +7 more
MS
Maxwell Skor
H.C. Wainwright & Co.
5 questions for INSM
Also covers: ASND, AVIR, CRNX +4 more
NG
Nicole Germino
Truist Securities
5 questions for INSM
Also covers: CRIS, GILD, SGMO +1 more
SW
Stephen Willey
Stifel Financial Corp.
4 questions for INSM
Also covers: ABCL, CELC, CGEN +10 more
Andy Chen
Wolfe Research, LLC
3 questions for INSM
Also covers: ARGX, CRNX, IMVT +7 more
JH
Jeff Hung
Morgan Stanley
3 questions for INSM
Also covers: ACAD, ALEC, BHVN +10 more
Leonid Timashev
RBC Capital Markets
3 questions for INSM
Also covers: ADCT, ALKS, AXSM +8 more
AT
Andrea Tan
Goldman Sachs
2 questions for INSM
Also covers: ABCL, ARWR, DAWN +3 more
AV
Ash Verma
UBS
2 questions for INSM
Also covers: ALVO, AVDL, EXEL +5 more
Ben Burnett
Stifel
2 questions for INSM
Also covers: ALKS, ALLO, FATE +1 more
CH
Chong Hun
UBS
2 questions for INSM
Clara Dong
Jefferies
2 questions for INSM
Also covers: AUTL, HRTX, LEGN +1 more
Gavin Clark-Gartner
Evercore ISI
2 questions for INSM
Also covers: ACRS, ARGX, ASND +11 more
LT
Lena Times
RBC Capital Markets
2 questions for INSM
LW
Leon Wang
Barclays
2 questions for INSM
Matthew Phipps
William Blair
2 questions for INSM
Also covers: ABBV, AGEN, AMGN +8 more
OB
Olivia Brayer
Cantor
2 questions for INSM
Also covers: AMGN, AUPH, BMRN +8 more
SL
Sam Long
Mizuho
2 questions for INSM
SW
Stephen Willey
Stifel
2 questions for INSM
Also covers: ABCL, ABEO, CGEN +7 more
AC
Andy Chan
Wolfe Research
1 question for INSM
Also covers: IMVT
AC
Andy Chin
Wolfe Research
1 question for INSM
AH
Andy Hsieh
William Blair & Company
1 question for INSM
Also covers: ALT, BYSI, CRDF +8 more
Brandon Frith
Wolfe Research, LLC
1 question for INSM
Also covers: NTLA, ROIV
Kelly Shi
Jefferies
1 question for INSM
Also covers: ADCT, AGEN, ALDX +17 more
TH
Trung Ho
UBS
1 question for INSM
TH
Trung Huynh
UBS Group AG
1 question for INSM
Also covers: ABBV, ABOS, AMGN +5 more
Recent press releases and 8-K filings for INSM.
Insmed Reports Strong BRINSUPRI Launch and ARIKAYCE Growth, Outlines 2026 Catalysts
INSM
Guidance Update
Product Launch
New Projects/Investments
- BRINSUPRI demonstrated strong initial U.S. launch performance, with ~9,000 new patient starts in Q4 2025 and ~11,550 cumulative patients by December 31, 2025, contributing to a market capitalization increase from ~$4 billion in April 2024 to ~$37 billion by December 2025 following its U.S. approval. However, the company anticipates Q1 2026 will see out-of-pocket reset dynamics, increased rebating, and stricter access criteria.
- ARIKAYCE reported preliminary unaudited worldwide revenue of ~$433.8 million for FY 2025, representing 19.3% growth over the prior year, and provided FY 2026 revenue guidance of $450 million to $470 million worldwide. The topline data readout for the ENCORE Phase 3 trial is expected in March/April 2026.
- The company is poised for future growth with numerous upcoming catalysts in 2026, including BRINSUPRI launches in the EU, UK, and Japan, and the initiation of multiple Phase 3 trials for TPIP in PAH, PPF, and IPF. These initiatives are supported by a strong cash position of $1.7 billion as of September 30, 2025.
3 days ago
Insmed Provides Updates on Brensocatib Launch, Arikayce Guidance, and Pipeline Progress
INSM
Guidance Update
Product Launch
New Projects/Investments
- Insmed's Brensocatib generated $144.6 million in revenue during its first full fourth quarter (Q4 2025), adding 9,000 patients for a cumulative total of over 11,500 since its August 2025 launch.
- Arikayce exceeded its previous year's guidance and is projected to achieve $450-$470 million in revenue for the full year 2026.
- The company is advancing its pipeline with TPIP pursuing four Phase 3 programs (PH-ILD, PAH, PPF, IPF) and has initiated enrollment in new gene therapy programs for DMD and ALS.
- Insmed reported a strong financial position with $1.7 billion in cash as of the end of September 2025.
3 days ago
Insmed Provides Commercial and Pipeline Updates at J.P. Morgan Healthcare Conference
INSM
Product Launch
Guidance Update
New Projects/Investments
- Insmed reported strong initial commercial performance for Brensocatib, with $144.6 million in revenue in its first full quarter (Q4 2025) and a cumulative total of more than 11,500 patients since its August 2025 launch. The company projects over $5 billion in peak revenue for Brensocatib in non-cystic fibrosis bronchiectasis.
- The company provided FY 2026 revenue guidance for Arikayce of $450-$470 million and highlighted the Encore trial for frontline MAC patients as a significant expansion opportunity.
- Insmed is advancing a robust pipeline, including four parallel Phase 3 programs for TPIP (PH-ILD, PAH, PPF, IPF). The CEDAR trial for Brensocatib in hidradenitis suppurativa is expected to read out in Q2 2026.
- The company maintains a strong financial position with $1.7 billion in cash as of the end of September.
3 days ago
Insmed Reports Strong BRINSUPRI Launch and Provides 2026 Outlook
INSM
Product Launch
Guidance Update
New Projects/Investments
- BRINSUPRI generated $144.6 million in revenue in its first full fourth quarter, adding 9,000 patients for a cumulative total of 11,500 since its August launch. International launches are planned for Europe and the UK in the first half of 2026, and Japan in the second half of 2026.
- ARIKAYCE surpassed its previous guidance and is projected to achieve $450-$470 million in revenue for the full year 2026. The ENCORE trial, if successful, could expand its target market from approximately 30,000 to over 200,000 patients.
- The company initiated the PALM-ILD study (Phase 3) for TPIP in December 2025 and expects to imminently start the PAH Phase 3 program, building on Phase 2 data showing a 33.9% reduction in pulmonary vascular resistance.
- Insmed's market capitalization has grown by an average of $2 billion per month over the last 18 months, with more commercial and clinical milestones anticipated in the next 18 months.
3 days ago
Insmed Reports Preliminary 2025 Revenues and Provides 2026 Outlook
INSM
Earnings
Guidance Update
New Projects/Investments
- Insmed reported preliminary unaudited total revenues for BRINSUPRI of approximately $144.6 Million for Q4 2025 (its first full quarter of launch) and approximately $172.7 Million for Full-Year 2025.
- ARIKAYCE achieved preliminary unaudited global revenues of approximately $433.8 Million for Full-Year 2025, exceeding its guidance, and Full-Year 2026 global ARIKAYCE revenues are expected to be between $450 Million and $470 Million.
- Key clinical trial updates include anticipated topline data from the Phase 3 ENCORE Study of ARIKAYCE in March or April of 2026, and from the Phase 2b CEDAR Study of Brensocatib in the Second Quarter of 2026.
- The Phase 3 PALM-ILD Study of TPIP was initiated in Q4 2025, with additional Phase 3 studies for PAH, PPF, and IPF planned for 2026.
6 days ago
Insmed Provides 2025 Preliminary Revenue and 2026 Outlook
INSM
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- Insmed reported preliminary unaudited full-year 2025 total revenues of approximately $606.4 million, representing a 67% increase from $363.7 million in 2024.
- ARIKAYCE global revenues for full-year 2025 were approximately $433.8 million, exceeding the upper end of guidance. The company expects 2026 global ARIKAYCE revenues to be between $450 million and $470 million.
- BRINSUPRI generated approximately $172.7 million in total revenues for full-year 2025, with approximately $144.6 million in its first full quarter of launch. The European Commission approved BRINSUPRI in November 2025, with an EU launch planned for the first half of 2026.
- Key clinical milestones include topline data from the Phase 3 ENCORE study for ARIKAYCE anticipated in March or April of 2026, and topline data from the Phase 2b CEDAR study for brensocatib expected in the second quarter of 2026.
6 days ago
Insmed Under Investigation Following Failed Clinical Trial and Stock Decline
INSM
Legal Proceedings
- Pomerantz LLP is investigating Insmed (INSM) for potential securities fraud or unlawful business practices on behalf of investors.
- The investigation follows Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study of brensocatib failed to meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development.
- Following this news, Insmed's stock price fell $31.91 per share, or 16.08%, closing at $166.55 per share on December 18, 2025.
7 days ago
Insmed Faces Investigation Following Failed Drug Study
INSM
Legal Proceedings
New Projects/Investments
- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (INSM) concerning potential securities fraud or unlawful business practices by the company and its officers/directors.
- The investigation stems from Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study of brensocatib failed to meet primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development.
- Following this news, Insmed's stock price fell $31.91 per share, or 16.08%, to close at $166.55 per share on December 18, 2025.
Jan 1, 2026, 3:00 PM
Insmed Faces Investor Investigation Following Failed Drug Trial
INSM
Legal Proceedings
New Projects/Investments
- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (INSM) concerning potential securities fraud or other unlawful business practices by the company's officers and/or directors.
- The investigation follows Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study of brensocatib did not meet its primary or secondary efficacy endpoints.
- As a result of the trial results, Insmed decided to discontinue the development of brensocatib.
- Following this news, Insmed's stock price fell $31.91 per share, or 16.08%, to close at $166.55 per share on December 18, 2025.
Dec 30, 2025, 5:37 PM
Insmed Faces Fraud Investigation Following Failed Drug Study
INSM
Legal Proceedings
New Projects/Investments
- The Schall Law Firm is investigating Insmed Incorporated (INSM) for potential violations of securities laws, focusing on whether the company issued false or misleading statements.
- This investigation follows Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints.
- As a direct consequence of the study results, Insmed stated it would discontinue the development of brensocatib.
- Following this news, Insmed's shares experienced a nearly 16.1% decline on the subsequent day.
Dec 30, 2025, 2:29 AM
Quarterly earnings call transcripts for INSMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more